Ensign Peak Advisors
VIGL

Ensign Peak Advisors’s Vigil Neuroscience VIGL Stock Holding History

Ensign Peak Advisors’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,578,116
Closed -$2.81M – 1720
2025
Q1 		$2.81M Buy
1,578,116
+875,000
+124% +$1.96M 0.01% 787
2024
Q4 		$1.2M Buy
703,116
+97,580
+16% +$288K ﹤0.01% 1209
2024
Q3 		$2.06M Buy
605,536
+210,420
+53% +$779K ﹤0.01% 938
2024
Q2 		$1.58M Buy
395,116
+166,442
+73% +$570K ﹤0.01% 1014
2024
Q1 		$780K Hold
228,674
– – ﹤0.01% 1475
2023
Q4 		$773K Buy
228,674
+216,750
+1,818% +$1.12M ﹤0.01% 1518
2023
Q3 		$64.3K Buy
+11,924
New +$82.4K ﹤0.01% 1747

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Ensign Peak Advisors's VIGL Position: Q2 2025 in Review

Ensign Peak Advisors sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 1,578,116 shares — an estimated $2.81M sold.

Ensign Peak Advisors first reported a position in VIGL in Q3 2023 and held it in 7 quarters. The position peaked at $2.81M in Q1 2025. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • Ensign Peak Advisors reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 1,578,116 Vigil Neuroscience shares in Q2 2025, an estimated $2.81M.
  • Ensign Peak Advisors first reported a position in Vigil Neuroscience in Q3 2023 and held it in 7 quarters.
  • Ensign Peak Advisors's Vigil Neuroscience position peaked at $2.81M in Q1 2025.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on Ensign Peak Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.